Published in Proc Natl Acad Sci U S A on February 17, 1998
Cyclophilin A regulates HIV-1 infectivity, as demonstrated by gene targeting in human T cells. EMBO J (2001) 2.64
Catalysis of cis/trans isomerization in native HIV-1 capsid by human cyclophilin A. Proc Natl Acad Sci U S A (2002) 2.19
Envelope-dependent, cyclophilin-independent effects of glycosaminoglycans on human immunodeficiency virus type 1 attachment and infection. J Virol (2002) 2.11
CD147 immunoglobulin superfamily receptor function and role in pathology. Exp Mol Pathol (2007) 1.77
CD147 facilitates HIV-1 infection by interacting with virus-associated cyclophilin A. Proc Natl Acad Sci U S A (2001) 1.69
Plunder and stowaways: incorporation of cellular proteins by enveloped viruses. J Virol (2005) 1.56
The B-oligomer of pertussis toxin deactivates CC chemokine receptor 5 and blocks entry of M-tropic HIV-1 strains. J Exp Med (1999) 1.30
Interaction with glycosaminoglycans is required for cyclophilin B to trigger integrin-mediated adhesion of peripheral blood T lymphocytes to extracellular matrix. Proc Natl Acad Sci U S A (2002) 1.30
Roles of cyclophilins in cancers and other organ systems. World J Surg (2005) 1.14
Cyclophilin a plays distinct roles in human immunodeficiency virus type 1 entry and postentry events, as revealed by spinoculation. J Virol (2002) 1.05
Involvement of two classes of binding sites in the interactions of cyclophilin B with peripheral blood T-lymphocytes. Biochem J (1998) 0.96
Effects of altered cyclophilin A expression on growth and differentiation of human and mouse neuronal cells. Cell Mol Neurobiol (2001) 0.95
Microbial peptidyl-prolyl cis/trans isomerases (PPIases): virulence factors and potential alternative drug targets. Microbiol Mol Biol Rev (2014) 0.93
Cyclophilin A-independent replication of a human immunodeficiency virus type 1 isolate carrying a small portion of the simian immunodeficiency virus SIV(MAC) gag capsid region. J Virol (2001) 0.92
Structural, biochemical, and in vivo characterization of the first virally encoded cyclophilin from the Mimivirus. J Mol Biol (2007) 0.91
Structural consequences of cyclophilin A binding on maturational refolding in human immunodeficiency virus type 1 capsid protein. J Virol (2001) 0.89
Contribution of cyclophilin A to the regulation of inflammatory processes in rheumatoid arthritis. J Clin Immunol (2009) 0.88
CD147 stimulates HIV-1 infection in a signal-independent fashion. Biochem Biophys Res Commun (2007) 0.86
Unfolding the relationship between secreted molecular chaperones and macrophage activation states. Cell Stress Chaperones (2008) 0.86
TLR2 activation enhances HIV nuclear import and infection through T cell activation-independent and -dependent pathways. J Immunol (2011) 0.85
Heat shock protein-based therapeutic strategies against human immunodeficiency virus type 1 infection. Infect Dis Obstet Gynecol (1999) 0.84
Conformational plasticity of an enzyme during catalysis: intricate coupling between cyclophilin A dynamics and substrate turnover. Biophys J (2013) 0.83
Detailed characterization of a cyclophilin from the human malaria parasite Plasmodium falciparum. Biochem J (1998) 0.80
21-kDa polypeptide, a low-molecular-weight cyclophilin, is released from pollen of higher plants into the extracellular medium in vitro. Planta (2004) 0.79
The Lymantria dispar IPLB-Ld652Y cell line transcriptome comprises diverse virus-associated transcripts. Viruses (2011) 0.79
The cysteine residues of HIV-1 capsid regulate oligomerization and cyclophilin A-induced changes. Biophys J (2004) 0.79
Cyclophilin A as a New Therapeutic Target for Hepatitis C Virus-induced Hepatocellular Carcinoma. Korean J Physiol Pharmacol (2013) 0.78
Differential loss of prolyl isomerase or chaperone activity of Ran-binding protein 2 (Ranbp2) unveils distinct physiological roles of its cyclophilin domain in proteostasis. J Biol Chem (2014) 0.78
A molecular dynamics study of Cyclophilin A free and in complex with the Ala-Pro dipeptide. Eur Biophys J (2007) 0.78
Molecular Architecture of the Retroviral Capsid. Trends Biochem Sci (2016) 0.77
Extracellular cyclophilins in health and disease. Biochim Biophys Acta (2014) 0.76
Dynamics and regulation of nuclear import and nuclear movements of HIV-1 complexes. PLoS Pathog (2017) 0.75
Protein folding in the cell. Nature (1992) 19.60
A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature (1993) 10.36
Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J Exp Med (1988) 9.21
Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins. Nature (1989) 8.48
Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell (1993) 7.34
Specific incorporation of cyclophilin A into HIV-1 virions. Nature (1994) 7.13
Functional association of cyclophilin A with HIV-1 virions. Nature (1994) 6.82
Biological and biochemical characterization of a cloned Leu-3- cell surviving infection with the acquired immune deficiency syndrome retrovirus. J Exp Med (1986) 6.52
Association of integrase, matrix, and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection. Proc Natl Acad Sci U S A (1993) 6.44
Human immunodeficiency virus type 1 preintegration complexes: studies of organization and composition. J Virol (1997) 5.73
Assembly and morphology of HIV: potential effect of structure on viral function. AIDS (1991) 4.73
Partial reverse transcripts in virions from human immunodeficiency and murine leukemia viruses. J Virol (1992) 4.72
HIV-1 infection of nondividing cells: C-terminal tyrosine phosphorylation of the viral matrix protein is a key regulator. Cell (1995) 4.41
Cyclophilin A is required for an early step in the life cycle of human immunodeficiency virus type 1 before the initiation of reverse transcription. J Virol (1996) 4.15
HIV entry and tropism: the chemokine receptor connection. AIDS (1997) 3.32
Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem (1992) 3.06
The mechanism of protein folding. Implications of in vitro refolding models for de novo protein folding and translocation in the cell. Biochemistry (1990) 2.68
Peptidylproline cis-trans-isomerases: immunophilins. Eur J Biochem (1993) 2.46
Cyclosporine A-resistant human immunodeficiency virus type 1 mutants demonstrate that Gag encodes the functional target of cyclophilin A. J Virol (1996) 2.39
Identification of cyclophilin as a proinflammatory secretory product of lipopolysaccharide-activated macrophages. Proc Natl Acad Sci U S A (1992) 2.20
Spontaneous mutations in the human immunodeficiency virus type 1 gag gene that affect viral replication in the presence of cyclosporins. J Virol (1996) 2.07
Analysis and localization of cyclophilin A found in the virions of human immunodeficiency virus type 1 MN strain. AIDS Res Hum Retroviruses (1995) 2.01
Synthesis and applications of a new poly(ethylene glycol) derivative for the crosslinking of amines with thiols. Bioconjug Chem (1995) 1.69
Transfer of the HIV-1 cyclophilin-binding site to simian immunodeficiency virus from Macaca mulatta can confer both cyclosporin sensitivity and cyclosporin dependence. Proc Natl Acad Sci U S A (1997) 1.68
Leukocyte chemotactic activity of cyclophilin. J Biol Chem (1992) 1.63
A novel secreted cyclophilin-like protein (SCYLP). J Biol Chem (1991) 1.52
Inhibition of human immunodeficiency virus replication by nonimmunosuppressive analogs of cyclosporin A. Proc Natl Acad Sci U S A (1995) 1.42
Presence of cyclophilin A in synovial fluids of patients with rheumatoid arthritis. J Exp Med (1997) 1.31
Crystal structure implies that cyclophilin predominantly catalyzes the trans to cis isomerization. Biochemistry (1996) 1.26
S-cyclophilin. New member of the cyclophilin family associated with the secretory pathway. J Biol Chem (1991) 1.20
Characterization of surface binding sites for cyclophilin B on a human tumor T-cell line. J Biol Chem (1994) 0.95
Basic fibroblast growth factor induces 3T3 fibroblasts to synthesize and secrete a cyclophilin-like protein and beta 2-microglobulin. Biochim Biophys Acta (1991) 0.93
Immunosuppressive activity of [MeBm2t]1-, D-diaminobutyryl-8-, and D-diaminopropyl-8-cyclosporin analogues correlates with inhibition of calcineurin phosphatase activity. J Immunol (1993) 0.90
Distribution of cyclophilin B-binding sites in the subsets of human peripheral blood lymphocytes. Immunology (1997) 0.85
On the historical origins of HIV-1 (MN) and (RF). AIDS Res Hum Retroviruses (1992) 0.78
Identification of a common nucleotide sequence in the 3'-untranslated region of mRNA molecules specifying inflammatory mediators. Proc Natl Acad Sci U S A (1986) 15.20
Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature (1988) 13.42
Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature (1986) 11.09
Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med (1986) 10.91
The biology of cachectin/TNF--a primary mediator of the host response. Annu Rev Immunol (1989) 9.63
Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. Science (1986) 9.19
Cachectin: more than a tumor necrosis factor. N Engl J Med (1987) 8.74
Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells. J Exp Med (1985) 8.18
Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med (1985) 8.16
Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med (1988) 7.96
A survey of childhood asthma in Aberdeen. Lancet (1969) 7.86
Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J Immunol (2001) 7.40
Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature (1985) 7.22
The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem (1991) 7.22
Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med (1988) 7.22
Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med (1994) 7.19
Correlation of glucose regulation and hemoglobin AIc in diabetes mellitus. N Engl J Med (1976) 7.02
TNF concentration in fatal cerebral, non-fatal cerebral, and uncomplicated Plasmodium falciparum malaria. Lancet (1990) 6.32
Estimates of bacterial growth from changes in uptake rates and biomass. Appl Environ Microbiol (1982) 6.11
Selective sorption of bacteria from seawater. Can J Microbiol (1971) 5.85
Tumor necrosis, cachexia, shock, and inflammation: a common mediator. Annu Rev Biochem (1988) 5.75
MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature (1993) 5.60
The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med (1994) 5.55
Contribution of particle-bound bacteria to total microheterotrophic activity in five ponds and two marshes. Appl Environ Microbiol (1982) 5.39
Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. J Immunol (1985) 5.38
MIF as a glucocorticoid-induced modulator of cytokine production. Nature (1995) 5.21
Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A (2000) 5.20
Macrophages secrete a novel heparin-binding protein with inflammatory and neutrophil chemokinetic properties. J Exp Med (1988) 5.16
A macrophage factor inhibits adipocyte gene expression: an in vitro model of cachexia. Science (1985) 4.98
Accelerated age-related browning of human collagen in diabetes mellitus. Proc Natl Acad Sci U S A (1984) 4.04
Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J Exp Med (1988) 4.02
Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med (1994) 3.95
Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med (2000) 3.89
Identification and characterization of macrophage inflammatory protein 2. Proc Natl Acad Sci U S A (1989) 3.88
Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med (1991) 3.81
Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A (2001) 3.80
An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci U S A (1996) 3.79
Studies of endotoxin-induced decrease in lipoprotein lipase activity. J Exp Med (1981) 3.70
Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest (1994) 3.70
Lipoprotein lipase suppression in 3T3-L1 cells by an endotoxin-induced mediator from exudate cells. Proc Natl Acad Sci U S A (1982) 3.69
Tumor necrosis factor, other cytokines and disease. Annu Rev Cell Biol (1993) 3.68
Macrophage inflammatory proteins 1 and 2: members of a novel superfamily of cytokines. FASEB J (1989) 3.67
Inhibition by chloroquine of a novel haem polymerase enzyme activity in malaria trophozoites. Nature (1992) 3.67
Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). Biochemistry (1994) 3.58
Metabolism and functions of trypanothione in the Kinetoplastida. Annu Rev Microbiol (1992) 3.57
The role of cachectin/TNF in endotoxic shock and cachexia. Immunol Today (1988) 3.40
Statistical analysis of the direct count method for enumerating bacteria. Appl Environ Microbiol (1982) 3.37
Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science (1986) 3.36
Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet (1988) 3.30
HCV confirmatory testing of blood donors. Lancet (1991) 3.29
Potassium cyanate as an inhibitor of the sickling of erythrocytes in vitro. Proc Natl Acad Sci U S A (1971) 3.27
Nonenzymatic browning in vivo: possible process for aging of long-lived proteins. Science (1981) 3.25
Nonenzymatic glycosylation and the pathogenesis of diabetic complications. Ann Intern Med (1984) 3.14
Regulated production of type I collagen and inflammatory cytokines by peripheral blood fibrocytes. J Immunol (1998) 3.09
Cloning and characterization of a cDNA for murine macrophage inflammatory protein (MIP), a novel monokine with inflammatory and chemokinetic properties. J Exp Med (1988) 3.06
Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem (1992) 3.06
Hypertriglyceridemia associated with Trypanosoma brucei brucei infection in rabbits: role of defective triglyceride removal. Mol Biochem Parasitol (1980) 3.05
Hemoglobin degradation in the malaria parasite Plasmodium falciparum: an ordered process in a unique organelle. Proc Natl Acad Sci U S A (1990) 3.01
Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest (1991) 3.00
Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nat Med (1997) 2.98
Trypanothione: a novel bis(glutathionyl)spermidine cofactor for glutathione reductase in trypanosomatids. Science (1985) 2.94
Viral hepatitis markers in blood donors and patients with a history of jaundice. Lancet (1980) 2.90
The role of cytokines in the generation of inflammation and tissue damage in experimental gram-positive meningitis. J Exp Med (1990) 2.89
Cachectin/tumour necrosis factor. Lancet (1989) 2.77
An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature (1996) 2.71
Cachectin/tumor necrosis factor exerts endocrine, paracrine, and autocrine control of inflammatory responses. J Cell Biol (1988) 2.66
Macrophage inflammatory protein 1 modulates macrophage function. J Immunol (1992) 2.66
Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action. J Biol Chem (1999) 2.60
Viral protein R regulates nuclear import of the HIV-1 pre-integration complex. EMBO J (1998) 2.56
Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J Intern Med (2008) 2.55
Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci U S A (1997) 2.53
Protein glycation, diabetes, and aging. Recent Prog Horm Res (2001) 2.51
The ghost of Christmas past: health effects of poverty in London in 1896 and 1991. BMJ (2001) 2.49
Health inequalities in Britain: continuing increases up to the end of the 20th century. J Epidemiol Community Health (2002) 2.46
Cloning and characterization of cDNAs for murine macrophage inflammatory protein 2 and its human homologues. J Exp Med (1990) 2.44
Tumour necrosis factor production in Falciparum malaria and its association with schizont rupture. Clin Exp Immunol (1989) 2.41
An iron-carboxylate bond links the heme units of malaria pigment. Proc Natl Acad Sci U S A (1991) 2.36
The peripheral blood fibrocyte is a potent antigen-presenting cell capable of priming naive T cells in situ. Proc Natl Acad Sci U S A (1997) 2.36
Identifying training and technical assistance needs in community coalitions: a developmental approach. Health Educ Res (1993) 2.34
Constitutive production of inflammatory and mitogenic cytokines by rheumatoid synovial fibroblasts. J Exp Med (1991) 2.32
Ecological aspects of microbial chemotactic behavior. Annu Rev Microbiol (1976) 2.31
The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting. Proc Natl Acad Sci U S A (2003) 2.29
Effect of gamma interferon on cachectin expression by mononuclear phagocytes. Reversal of the lpsd (endotoxin resistance) phenotype. J Exp Med (1986) 2.28
Aging of proteins: isolation and identification of a fluorescent chromophore from the reaction of polypeptides with glucose. Proc Natl Acad Sci U S A (1984) 2.26
Epithelial wound healing enhanced by transforming growth factor-alpha and vaccinia growth factor. Science (1987) 2.24
Weight loss associated with an endotoxin-induced mediator from peritoneal macrophages: the role of cachectin (tumor necrosis factor). Immunol Lett (1985) 2.23
The influence of the New Pathway curriculum on Harvard medical students. Acad Med (1994) 2.23
Tumor necrosis factor plays a protective role in experimental murine cutaneous leishmaniasis. J Exp Med (1989) 2.21
Recombinant interleukin 1 suppresses lipoprotein lipase activity in 3T3-L1 cells. J Immunol (1985) 2.21
A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. Genes Immun (2002) 2.21